{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-224156","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-05-14T20:28:56+00:00","discovered_at":"2026-05-14T20:30:00.297943+00:00","generated_at":"2026-05-14T20:40:45.407538+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Tempest Therapeutics reports Q1 2026 net loss of $27.7M, highlights 100% CR rate in TPST-2003 trials","bullets":["Ended Q1 with $1.8M cash vs $7.7M at year-end 2025; net loss $27.7M ($2.53/share) vs $10.9M ($3.16) year ago.","TPST-2003 showed 100% complete response in 15 CAR-T-naïve evaluable patients across two trials; no Grade ≥3 CRS/ICANS.","Selected Cincinnati Children's AGCTC as lead manufacturing partner; lentiviral vector received for TPST-2003.","Appointed Andrew Fang, Ph.D., as Head of Business Development to lead partnerships and licensing.","Completed asset acquisition of dual-targeting CAR-T assets from Factor Bioscience and Erigen; $6M private placement closed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-224156","json":"https://secwatch.observer/filing/0001193125-26-224156.json","markdown":"https://secwatch.observer/filing/0001193125-26-224156.md","text":"https://secwatch.observer/filing/0001193125-26-224156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526224156/0001193125-26-224156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526224156/tpst-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:40:45.407538+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b9cfb3fe0e1d2eec50533a5404695cd4c67df8c7","claim":"Tempest Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income $27.7 million, EPS $2.53.","evidence_excerpt":"Net loss and net loss per share for the quarter were $27.7 million and $2.53, respectively, compared to $10.9 million and $3.16, respectively, for the three months ended March 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526224156/0001193125-26-224156-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Net income","value":"$27.7 million"},{"label":"EPS","value":"$2.53"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}